FY2029 EPS Estimates for Denali Therapeutics Cut by Wedbush

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at Wedbush reduced their FY2029 EPS estimates for shares of Denali Therapeutics in a research note issued to investors on Friday, November 7th. Wedbush analyst L. Chico now forecasts that the company will post earnings of $1.08 per share for the year, down from their previous forecast of $1.27. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.63) earnings per share.

Other equities research analysts have also issued reports about the company. TD Cowen upgraded Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. JPMorgan Chase & Co. boosted their price objective on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Morgan Stanley dropped their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.64.

Denali Therapeutics Stock Up 4.2%

Shares of NASDAQ DNLI opened at $15.02 on Monday. The stock has a market cap of $2.20 billion, a PE ratio of -5.16 and a beta of 1.39. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33. The company has a 50-day moving average of $15.08 and a 200 day moving average of $14.68.

Insider Buying and Selling

In other news, insider Carole Ho sold 2,937 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider directly owned 217,391 shares in the company, valued at $2,952,169.78. This trade represents a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of Denali Therapeutics stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 242,346 shares of the company’s stock, valued at $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,680 shares of company stock valued at $91,569 in the last ninety days. 12.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors have recently bought and sold shares of DNLI. Headlands Technologies LLC purchased a new stake in Denali Therapeutics during the second quarter worth about $26,000. Caitong International Asset Management Co. Ltd increased its stake in Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after buying an additional 1,551 shares during the period. State of Wyoming acquired a new stake in Denali Therapeutics during the 2nd quarter worth approximately $29,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Denali Therapeutics during the 1st quarter worth approximately $41,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock valued at $79,000 after buying an additional 753 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.